A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 755 participants.

Also called NCT06066528

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 755 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06066528
  • EU CT 2022-502531-18-00
  • WHO UTN U1111-1289-0247
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Belgium, Canada, China, Czechia, Denmark, Finland, Germany, Greece, Hungary, Japan, Netherlands, New Zealand, Poland, South Korea, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06066528. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-27 (actual); primary completion 2025-12-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Acronym
SYNCHRONIZE™-2
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Combination product)
Survodutide
Intervention (Combination product)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct06066528
Content hash
224f211d88cf6b6a9cd9c10d43a89206d8ac05480b81568944c1348f7f4f5e68